Abstract
The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3–5.8). Quantitative reverse-transcription–polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA . (2006). How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 175: 1337–1340.
Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al. (2005). Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984.
Carver BS, Bianco Jr FJ, Scardino PT, Eastham JA . (2006). Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176: 564–568.
Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M et al. (2002). A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347: 781–789.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. (2006). Cancer statistics, 2006. CA Cancer J Clin 56: 106–130.
Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB . (1992). High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267: 2191–2196.
Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W . (1989). Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1: 799–803.
Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A et al. (2004). Natural history of early, localized prostate cancer. JAMA 291: 2713–2719.
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO . (1997). Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277: 467–471.
Kalbfleisch JD, Prentice RL . (2002). The Statistical Analysis of Failure Time Data. John Wiley: Hoboken, NJ.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S et al. (2006). TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337–8341.
Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J et al. TMPRSS2-ERG Fusion Prostate Cancer: an early molecular event associated with invasion. Am J Surg Pathol (in press).
Petrovics G, Liu A, Shaheduzzaman S, Furasato B, Sun C, Chen Y et al. (2005). Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24: 3847–3852.
Porter CR, Kodama K, Gibbons RP, Correa Jr R, Chun FK, Perrotte P et al. (2006). 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176: 569–574.
Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R et al. (2005). Decreased {alpha}-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14: 1424–1432.
R Development Core Team. (2006). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I . (2006). Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45: 717–719.
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE et al. (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66: 3396–3400.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.
Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H . (2003). The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872–1876.
Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB . (2006). Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98: 355–357.
Acknowledgements
This work was supported by the National Cancer Institute Prostate Cancer SPORE at the Dana-Farber/Harvard Cancer Center NCI P50 CA090381 (PWK and MAR), National Institute of Aging R01AG21404 (MAR and AMC), The Early Detection Research Network of the NCI UO1CA113913 (MAR and AMC), Deutsche Forschungsgemeinschaft DFG no. PE1179/1–1 (SP), the Prostate Cancer Foundation (FD) and the Department of Defense Prostate Cancer Program (KF). We appreciate the critical comments from Todd Golub and Meir Stampfer. We are grateful to Danielle Cullinane and Kelly Lamb for technical support critical to this study.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Demichelis, F., Fall, K., Perner, S. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596–4599 (2007). https://doi.org/10.1038/sj.onc.1210237
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210237
Keywords
This article is cited by
-
Metabolic syndrome is associated with aggressive prostate cancer regardless of race
Cancer Causes & Control (2023)
-
Genion, an accurate tool to detect gene fusion from long transcriptomics reads
BMC Genomics (2022)
-
PACE4-altCT isoform of proprotein convertase PACE4 as tissue and plasmatic biomarker for prostate cancer
Scientific Reports (2022)
-
Race and prostate cancer: genomic landscape
Nature Reviews Urology (2022)
-
Molecular events in neuroendocrine prostate cancer development
Nature Reviews Urology (2021)